Symptomatic treatment of neurologic symptoms in Wilson disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10364541" target="_blank" >RIV/00216208:11110/17:10364541 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10364541

Výsledek na webu

<a href="http://dx.doi.org/10.1016/B978-0-444-63625-6.00018-5" target="_blank" >http://dx.doi.org/10.1016/B978-0-444-63625-6.00018-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-444-63625-6.00018-5" target="_blank" >10.1016/B978-0-444-63625-6.00018-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Symptomatic treatment of neurologic symptoms in Wilson disease

Popis výsledku v původním jazyce

Wilson disease (WD) is a potentially treatable neurodegenerative disorder. In the majority of cases, treatment with drugs that induce a negative copper balance (usually chelators or zinc salts) leads to improvements in liver function and neurologic signs. However, some patients show severe neurologic symptoms at diagnosis, such as tremor, dystonia, parkinsonism, and chorea. In this patient group, some neurologic deficits may persist despite adequate treatment, and further neurologic deterioration may be observed after treatment initiation. Such patients may require additional treatment to alleviate neurologic symptoms. Apart from general recommendations for WD anticopper treatment, there are currently no guidelines for managing neurologic symptoms in WD. The aim of this chapter is to summarize possible treatments of neurologic symptoms in WD based on the presently available medical literature.

Název v anglickém jazyce

Symptomatic treatment of neurologic symptoms in Wilson disease

Popis výsledku anglicky

Wilson disease (WD) is a potentially treatable neurodegenerative disorder. In the majority of cases, treatment with drugs that induce a negative copper balance (usually chelators or zinc salts) leads to improvements in liver function and neurologic signs. However, some patients show severe neurologic symptoms at diagnosis, such as tremor, dystonia, parkinsonism, and chorea. In this patient group, some neurologic deficits may persist despite adequate treatment, and further neurologic deterioration may be observed after treatment initiation. Such patients may require additional treatment to alleviate neurologic symptoms. Apart from general recommendations for WD anticopper treatment, there are currently no guidelines for managing neurologic symptoms in WD. The aim of this chapter is to summarize possible treatments of neurologic symptoms in WD based on the presently available medical literature.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NV15-25602A" target="_blank" >NV15-25602A: Biomarkery progrese a terapeutické odpovědi u neurodegenerativních onemocnění</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Wilson disease

ISBN

978-0-444-63625-6

Počet stran výsledku

13

Strana od-do

211-223

Počet stran knihy

264

Název nakladatele

Elsevier Science

Místo vydání

Amsterdam

Kód UT WoS kapitoly

—